B+
Bull case
25%
Probability
Target price
$15.00
+108.3% vs current
UNCY
Unicycive TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$7.00
-2.8% vs current
B-
Bear case
30%
Probability
Target price
$3.00
-58.3% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+55.3
Score
AI commentary
Sentiment is best framed as cautious monitoring, not a clean bullish setup: deterministic signals are near-neutral, forward visibility is concentrated in one FDA date, and primary-source evidence still points to meaningful dilution and execution risk despite genuine commercial preparation [#10-K-2026-03-30].
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-05-15catalystQ1 2026 cash and ATM usage disclosureHigh impact
The next quarterly filing should clarify how much of the year-end $41.3M cash/investment balance remains after the company already sold 3.12M shares post-year-end for about $19.6M net proceeds under its Guggenheim sales agreement, a key read-through for dilution risk into the FDA decision window [#10-K-2026-03-30].
2026-06-29catalystFDA action on OLC NDA resubmissionHigh impact
The core value driver is the June 29, 2026 PDUFA date after FDA accepted the OLC NDA resubmission as a Class II response; approval would validate the lead asset, while another delay or rejection would materially impair the equity story [#10-K-2026-03-30].
2026-12-31catalystRunway extension and TDAPA-backed launch setupHigh impact
A more distant but still material path is whether Unicycive can secure enough capital or a strategic alliance to bridge toward a potential first-half 2027 OLC launch, where management argues TDAPA could provide separate reimbursement and a favorable dialysis-channel economic setup; the same 10-K makes clear additional capital is still needed and strategic alternatives remain under evaluation [#10-K-2026-03-30].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology